TWI926045B - 含氮雜環類化合物、其製備方法及其在醫藥上的應用 - Google Patents
含氮雜環類化合物、其製備方法及其在醫藥上的應用Info
- Publication number
- TWI926045B TWI926045B TW111119308A TW111119308A TWI926045B TW I926045 B TWI926045 B TW I926045B TW 111119308 A TW111119308 A TW 111119308A TW 111119308 A TW111119308 A TW 111119308A TW I926045 B TWI926045 B TW I926045B
- Authority
- TW
- Taiwan
- Prior art keywords
- compound
- halogen
- general formula
- alkyl
- cancer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110565410 | 2021-05-24 | ||
| CN202110565410.0 | 2021-05-24 | ||
| CN202110694022 | 2021-06-22 | ||
| CN202110694022.2 | 2021-06-22 | ||
| CN202110856289.7 | 2021-07-28 | ||
| CN202110856289 | 2021-07-28 | ||
| CN202210198679.4 | 2022-03-02 | ||
| CN202210198679 | 2022-03-02 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW202313630A TW202313630A (zh) | 2023-04-01 |
| TWI926045B true TWI926045B (zh) | 2026-05-21 |
Family
ID=84229501
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW111119308A TWI926045B (zh) | 2021-05-24 | 2022-05-24 | 含氮雜環類化合物、其製備方法及其在醫藥上的應用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240287094A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4349836A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024519188A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240012437A (cg-RX-API-DMAC7.html) |
| CN (1) | CN117177971A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022280845A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112023022496A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3219858A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023013890A (cg-RX-API-DMAC7.html) |
| TW (1) | TWI926045B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022247816A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI876212B (zh) | 2021-10-01 | 2025-03-11 | 美商辛瑟拉股份有限公司 | 吖丁啶及吡咯啶parp1抑制劑及其用途 |
| CN120081844A (zh) | 2022-01-21 | 2025-06-03 | 新特拉有限公司 | Parp1抑制剂及其用途 |
| US20250214980A1 (en) | 2022-03-14 | 2025-07-03 | Slap Pharmaceuticals Llc | Multicyclic compounds |
| PT4497438T (pt) | 2022-04-28 | 2025-10-31 | Xinthera Inc C/O Gilead Sciences Inc | Inibidores tricíclicos da parp1 e suas utilizações |
| EP4524142A4 (en) * | 2022-05-07 | 2026-07-01 | Scibrunch Therapeutics Co Ltd | FLUOROQUINOXALINONE DERIVATIVE FOR THE SELECTIVE INHIBITION OF PARP1 |
| WO2024041643A1 (zh) * | 2022-08-25 | 2024-02-29 | 江苏恒瑞医药股份有限公司 | 稠合三环类化合物、其制备方法及其在医药上的应用 |
| KR20250103773A (ko) * | 2022-11-23 | 2025-07-07 | 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 | 질소 함유 헤테로시클릭계 화합물의 약학적으로 사용 가능한 염, 결정형 및 제조 방법 |
| AU2023412594A1 (en) * | 2022-12-23 | 2025-07-10 | Zhejiang Yangli Pharmaceutical Technology Co., Ltd. | Parp1 inhibitors |
| JP2026524090A (ja) | 2023-06-08 | 2026-07-17 | 上海森▲輝▼医▲葯▼有限公司 | ホルムアミド系化合物の製造方法 |
| CN120677162A (zh) * | 2023-06-13 | 2025-09-19 | 中国医药研究开发中心有限公司 | 含氮杂环类化合物及其医药用途 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4138564A (en) * | 1977-08-03 | 1979-02-06 | American Home Products Corporation | Tetrahydro[1H]pyrazino[1,2-a]azaquinoxalin-5(6H)-ones and derivatives thereof |
| WO2021013735A1 (en) * | 2019-07-19 | 2021-01-28 | Astrazeneca Ab | Parp1 inhibitors |
| TW202309025A (zh) * | 2021-04-19 | 2023-03-01 | 美商辛瑟拉股份有限公司 | Parp1抑制劑及其用途 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPS137402A0 (en) * | 2002-03-26 | 2002-05-09 | Fujisawa Pharmaceutical Co., Ltd. | Novel tricyclic compounds |
| JP5545955B2 (ja) | 2007-03-08 | 2014-07-09 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Parpおよびtank阻害剤としてのキノリノン誘導体 |
| WO2009053373A1 (en) | 2007-10-26 | 2009-04-30 | Janssen Pharmaceutica Nv | Quinolinone derivatives as parp inhibitors |
| CN102372716A (zh) * | 2010-08-09 | 2012-03-14 | 江苏恒瑞医药股份有限公司 | 酞嗪酮类衍生物、其制备方法及其在医药上的应用 |
| TWI693218B (zh) | 2014-11-14 | 2020-05-11 | 美商美國禮來大藥廠 | 極光a激酶抑制劑 |
| WO2020098774A1 (zh) * | 2018-11-16 | 2020-05-22 | 江苏恒瑞医药股份有限公司 | 一种包含parp抑制剂的药物组合物 |
| CN116018132A (zh) | 2020-06-24 | 2023-04-25 | Itf研究制药有限公司 | 软明胶胶囊 |
| US11795158B2 (en) | 2020-06-25 | 2023-10-24 | Astrazeneca Ab | Chemical compounds |
| EP4524142A4 (en) * | 2022-05-07 | 2026-07-01 | Scibrunch Therapeutics Co Ltd | FLUOROQUINOXALINONE DERIVATIVE FOR THE SELECTIVE INHIBITION OF PARP1 |
-
2022
- 2022-05-24 AU AU2022280845A patent/AU2022280845A1/en active Pending
- 2022-05-24 EP EP22810541.7A patent/EP4349836A4/en active Pending
- 2022-05-24 US US18/562,127 patent/US20240287094A1/en active Pending
- 2022-05-24 CN CN202280027629.8A patent/CN117177971A/zh active Pending
- 2022-05-24 TW TW111119308A patent/TWI926045B/zh active
- 2022-05-24 WO PCT/CN2022/094612 patent/WO2022247816A1/zh not_active Ceased
- 2022-05-24 JP JP2024515728A patent/JP2024519188A/ja active Pending
- 2022-05-24 KR KR1020237042926A patent/KR20240012437A/ko active Pending
- 2022-05-24 BR BR112023022496A patent/BR112023022496A2/pt unknown
- 2022-05-24 MX MX2023013890A patent/MX2023013890A/es unknown
- 2022-05-24 CA CA3219858A patent/CA3219858A1/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4138564A (en) * | 1977-08-03 | 1979-02-06 | American Home Products Corporation | Tetrahydro[1H]pyrazino[1,2-a]azaquinoxalin-5(6H)-ones and derivatives thereof |
| WO2021013735A1 (en) * | 2019-07-19 | 2021-01-28 | Astrazeneca Ab | Parp1 inhibitors |
| TW202309025A (zh) * | 2021-04-19 | 2023-03-01 | 美商辛瑟拉股份有限公司 | Parp1抑制劑及其用途 |
Also Published As
| Publication number | Publication date |
|---|---|
| BR112023022496A2 (pt) | 2024-01-16 |
| CA3219858A1 (en) | 2022-12-01 |
| KR20240012437A (ko) | 2024-01-29 |
| CN117177971A (zh) | 2023-12-05 |
| EP4349836A4 (en) | 2024-10-30 |
| EP4349836A1 (en) | 2024-04-10 |
| US20240287094A1 (en) | 2024-08-29 |
| WO2022247816A1 (zh) | 2022-12-01 |
| AU2022280845A1 (en) | 2023-12-14 |
| TW202313630A (zh) | 2023-04-01 |
| MX2023013890A (es) | 2023-12-11 |
| JP2024519188A (ja) | 2024-05-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4273136A4 (en) | NITROGEN-CONTAINING BRIDGED HETEROCYCLIC COMPOUND, METHOD OF PREPARING THE SAME AND MEDICAL USE THEREOF | |
| EP4209490A4 (en) | CONDENSED IMIDAZOLE DERIVATIVE, PROCESS THEREOF AND MEDICAL USE THEREOF | |
| EP3907218A4 (en) | 6-OXO-1,6-DIHYDROPYRIDAZINE DERIVATIVE, METHOD FOR PREPARATION AND MEDICAL USE | |
| EP4015520A4 (en) | OXYGEN-CONTAINING HETEROCYCLIC COMPOUND, PROCESS FOR THEIR PRODUCTION AND ITS USE | |
| EP3865488A4 (en) | MACROCYCLIC COMPOUND AS CDK INHIBITOR, METHOD OF MANUFACTURING AND MEDICAL USE | |
| EP3539963A4 (en) | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, PREPARATION METHOD, INTERMEDIATE, PHARMACEUTICAL COMPOSITION AND USE | |
| EP4023659A4 (en) | COMPOUND AND DRUG CONJUGATE, PRODUCTION METHOD AND USE THEREOF | |
| EP4308549A4 (en) | Nitrogen-containing heterocyclic ketones, manufacturing processes and medicinal uses thereof | |
| EP4349828A4 (en) | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, PRODUCTION PROCESS THEREOF AND USE THEREOF | |
| EP3919489A4 (en) | AROMATIC RING OR HETEROAROMATIC RING COMPOUNDS, PROCESS FOR THEIR PRODUCTION AND MEDICAL USE | |
| EP4289843A4 (en) | PYRIDOPYRIMIDINONE DERIVATIVE, MANUFACTURE PROCESS THEREOF AND USE THEREOF | |
| EP3992194A4 (en) | BENZODIAZEPIN COMPOUND, METHOD OF MANUFACTURE AND USE THEREOF IN MEDICINE | |
| EP4238958A4 (en) | 2-CYANOACRYLATE COMPOUND, METHOD FOR PREPARING IT AND ITS USE | |
| EP4159733A4 (en) | BETA-LACTAM COMPOUND, USE THEREOF AND METHOD OF MANUFACTURING THEREOF | |
| EP4108766A4 (en) | Method for preparing fibrosis-encapsulated tumoroid, and use thereof | |
| EP4585596A4 (en) | Nitrogen-containing heterocyclic compound, pharmaceutical composition thereof and uses thereof | |
| ZA202209741B (en) | Dihydronaphthyridinone compound, and preparation method therefor and medical use thereof | |
| EP4065553A4 (en) | NEW COMPOUND, METHOD FOR PREPARATION AND USE | |
| EP4082556A4 (en) | PREPARATION OF COMPOUND FOR NERVOUS TISSUE REGENERATION, METHOD FOR PREPARATION AND USE | |
| HK40112858A (en) | Nitrogen-containing tetracyclic compound, preparation method therefor, and medical use thereof | |
| HK40104924A (en) | Nitrogen-containing heterocyclic compound, and preparation method thereof, intermediate thereof, and application thereof | |
| CA3274002A1 (en) | Heterocyclic compound, and preparation method therefor and use thereof | |
| HK40121001A (en) | Heterocyclic compound, and preparation method therefor and use thereof | |
| HK40122720A (en) | Heterocyclic compound, method for preparing same, and pharmaceutical use thereof | |
| CA3264205A1 (en) | Heterocyclic compound, method for preparing same, and pharmaceutical use thereof |